Organisms | Evidence |
---|---|
Mesocestoides vogae | |
Chlorocebus aethiops (grivet) | |
Oryctolagus cuniculus (rabbit) | |
Saccharomyces cerevisiae (brewer's yeast) | |
Taenia hydatigena |
Gene Symbol | Donor | Acceptor | Reducing terminal(Acceptor) | Product | Reducing terminal(Product) | Reference |
---|---|---|---|---|---|---|
C1GALT1 | (not applicable) |
|
Ser/Thr |
|
Ser/Thr | |
ST6GALNAC1 | CMP-Neu5Ac |
|
Ser/Thr |
|
Ser/Thr | |
ST6GALNAC1 | CMP-Neu5Ac |
|
O-glycan Synthesis |
|
O-glycan Synthesis | |
B3GNT6 | UDP-GlcNAc |
|
[alpha]-pNP |
|
[alpha]-pNP |
Gene Symbol | Donor | Acceptor | Reducing terminal(Acceptor) | Product | Reducing terminal(Product) | Reference |
---|---|---|---|---|---|---|
C1GALT1 | (not applicable) |
|
Ser/Thr |
|
Ser/Thr | |
ST6GALNAC1 | CMP-Neu5Ac |
|
Ser/Thr |
|
Ser/Thr | |
ST6GALNAC4 | CMP-Neu5Ac |
|
benzyl |
|
benzyl | |
ST6GALNAC1 | CMP-Neu5Ac |
|
O-glycan Synthesis |
|
O-glycan Synthesis | |
ST6GALNAC1 | CMP-Neu5Ac |
|
[Ala-Thr(*)-Ala]2-7 |
|
[Ala-Thr(*)-Ala]2-7 |
Gene Symbol | Donor | Acceptor | Reducing terminal(Acceptor) | Reference |
---|---|---|---|---|
ST6GALNAC3 | CMP-Neu5Ac |
|
Ser/Thr | |
ST6GAL2 | CMP-Neu5Ac |
|
para-nitrophenol | |
ST6GALNAC2 | CMP-Neu5Ac |
|
benzyl | |
ST6GALNAC1 | CMP-Neu5Ac |
|
[alpha]-Bz | |
ST6GALNAC2 | CMP-Neu5Ac |
|
Ser/Thr |
Pathway Name | Organism |
---|---|
Ficolins bind to repetitive carbohydrate structures on the target cell surface | Sus scrofa |
Initial triggering of complement | Mus musculus |
Initial triggering of complement | Gallus gallus |
Initial triggering of complement | Xenopus tropicalis |
Initial triggering of complement | Sus scrofa |
Initial triggering of complement | Bos taurus |
Initial triggering of complement | Canis familiaris |
Initial triggering of complement | Rattus norvegicus |
Initial triggering of complement | Homo sapiens |
Lectin pathway of complement activation | Bos taurus |
RES 1b:a-dgal-HEX-1:5 2s:n-acetyl LIN 1:1d(2+1)2n
PubMed ID | Title | First Author | Publication Date | Source |
---|---|---|---|---|
35058124 | Givosiran in acute intermittent porphyria: A personalized medicine approach | Poli A | 2022 Mar |
|
35737426 | Preclinical Toxicological Assessment of A Novel siRNA, SLN360, Targeting Elevated Lipoprotein (a) in Cardiovascular Disease | Rider D | 2022 Jun 23 |
|
35745067 | Properties of Parallel Tetramolecular G-Quadruplex Carrying N-Acetylgalactosamine as Potential Enhancer for Oligonucleotide Delivery to Hepatocytes | Clua A | 2022 Jun 20 |
|
35734365 | Spotlight on Givosiran as a Treatment Option for Adults with Acute Hepatic Porphyria: Design, Development, and Place in Therapy | Majeed CN | 2022 Jun |
|
34154993 | The Nonclinical Disposition and Pharmacokinetic/Pharmacodynamic Properties of N-Acetylgalactosamine–Conjugated Small Interfering RNA Are Highly Predictable and Build Confidence in Translation to Human | McDougall R | 2022 Jun |
|
35887043 | Identification of Multiple Domains of Entamoeba histolytica Intermediate Subunit Lectin-1 with Hemolytic and Cytotoxic Activities | Kato K | 2022 Jul 12 |
|
35791075 | Glucose Transport through N-Acetylgalactosamine Phosphotransferase System in Escherichia coli C Strain | Kim HJ | 2022 Jul 04 |
|
35067977 | RNAi therapy with givosiran significantly reduces attack rates in acute intermittent porphyria | Sardh E | 2022 Jan 23 |
|
35053234 | Towards Mapping of the Human Brain N-Glycome with Standardized Graphitic Carbon Chromatography | Helm J | 2022 Jan 06 |
|
34871941 | Purification of N-acetylgalactosamine-modified-oligonucleotides using orthogonal anion-exchange and mixed-mode chromatography approaches | Kazarian AA | 2022 Jan 04 |
|
GlyCosmos is a member of the GlySpace Alliance together with GlyGen and Glycomics@ExPASy.
Supported by JST NBDC Grant Number JPMJND2204
Partly supported by NIH Common Fund Grant #1U01GM125267-01
This work is licensed under Creative Commons Attribution 4.0 International
GlyCosmos Portal v4.2.1
Last updated: April 7, 2025